Status:
UNKNOWN
Evaluation of a Cosmetic Product to Preserve Skin Conditions When Using Anti-EGFR Cancer Therapies
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Carcinoma, Non-Small-Cell Lung
Colorectal Neoplasms
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
It is important for patients treated with anti-EGFR therapies to get access to cosmetic options to preserve their skin condition during treatment. Anti-EGFR therapies are known to fragilize epidermis ...
Eligibility Criteria
Inclusion
- Patient \> 18 years old
- Patient naive from anti-EGFR treatment (gefitinib, erlotinib, afatinib, cetuximab panitumumab, osimertinib, alectinib et crizotinib, etc).
- NSCLC (non-small cell lung cancer) patients eligible to anti-EGFR as first line treatment (gefitinib, erlotinib,afatinib, etc)
- Colorectal cancer patients eligible to anti-EGFR as first line treatment (cetuximab, panitumumab,….)
- Head and Neck/ENT (Ear, Nose Troat) cancer patients eligible to anti-EGFR as first line treatment (cetuximab,…)
- Signed informed consent
- Social security affiliation
Exclusion
- Pregnant or Breastfeeding patient
- Patient in age to procreate without an efficient contraceptive method
- Patient with previous experience of allergic or irritative contact dermatitis to components of the studied product
- Patient with dermatologic conditions that cannot permit the study of skin toxicity of anti-EGFR
- Patients under radiotherapy 8 days prior the inclusion date
- Patient under immunotherapy 8 days prior the inclusion date
- Patient with local or systemic antibiotic treatment for acne 8 days prior the inclusion date
- Patient with antihistamines treatment 8 days prior the inclusion date
- Patients taking NSAIDs or corticoids as chronic medication or that took NSAIDs or corticoids 5 days prior the inclusion date
- Participation to another interventional study
- Patient with an altered ECOG (Eastern Cooperative Oncology Group) state ( \>2)
- Patient deprived of liberty or subjected to guardianship
- Impossibility to track and follow patient for geographical, social or psychiatric reasons.
Key Trial Info
Start Date :
June 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2022
Estimated Enrollment :
96 Patients enrolled
Trial Details
Trial ID
NCT04878692
Start Date
June 1 2021
End Date
July 1 2022
Last Update
May 7 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut de Cancérologie des Hospices Civils de Lyon - Service Oncologie Médicale - Centre Hospitalier Lyon Sud
Pierre-Bénite, France, 69495